Juan Eirís del Río

Dr. Juan Eirís del Río

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
PCPedro Chorão
Pedro Chorão
MHMarta Henriques
Marta Henriques
MVMarta Villalba
Marta Villalba
JMJuan Montoro
Juan Montoro
ABAitana Balaguer-Roselló
Aitana Balaguer-Roselló
JSJaime Sanz
Jaime Sanz
Cytomegalovirus (CMV) reactivations cause significant morbidity in allogeneic hematopoietic stem cell transplantation (HSCT) recipients. Graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy) is associated with an increased risk of CMV infections. Data are limited comparing HSCT with PTCy performed from matched sibling donors (MSDs), matched unrelated donors (MUDs), and haploidentical (Haplo) donors. In the present study, we aimed to characterize CMV reactivation and recurrence in patients with hematologic malignancies undergoing HSCT from MSD, MUD, and Haplo donors using PTCy as GVHD prophylaxis in the pre-letermovir era. We also analyzed risk factors of CMV reactivation, including GVHD as a time-dependent variable, on the incidence and mortality associated with CMV infections. We analyzed CMV reactivation in patients undergoing HSCT from 160 MSDs, 124 MUDs, and 82 Haplo donors from a single institution. Uniform GVHD prophylaxis with PTCy, sirolimus, and mycophenolate mofetil was given irrespective of donor type. Overall, 46% of patients had at least 1 CMV reactivation. The 1-year cumulative incidence of CMV infection was 39% for MSD, 44% for MUD, and 62% for Haplo donors (P < .001), with 96% of reactivations occurring before day +100. Multivariate analysis identified factors associated with the first CMV reactivation, including Haplo donor, positive recipient CMV serology, older patient age, and grade II-IV acute GVHD. The 1-year cumulative incidence of second reactivation from HSCT was 13%. Recipient CMV seropositivity, older patient age, and grade II-IV acute GVHD, but not type of donor, were identified as adverse factors for second CMV reactivation in multivariate analysis. The 1-year cumulative incidence of a third reactivation post HSCT was 4.4%. Ten cases of CMV disease were recorded, with no attributable deaths. Nevertheless, the risk for nonrelapse mortality was greater for patients who experienced CMV reactivation in multivariate time-dependent Cox model analysis. CMV reactivation is frequent in HSCT with PTCy in patients not receiving letermovir prophylaxis. Identified risk factors include the use of a Haplo donor, recipient CMV seropositivity, and grade II-IV acute GVHD. The prevalence of recurrent CMV reactivations is a noteworthy issue, especially after acute GVHD, warranting trials of secondary prophylaxis strategies.

24 August 2024 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
PCPedro Asensi Cantó
Pedro Asensi Cantó
ISINES GOMEZ SEGUÍ
INES GOMEZ SEGUÍ
JMJ. Montoro
J. Montoro
MMM. Villalba Montaner
M. Villalba Montaner
PCPedro Chorão
Pedro Chorão
JSJ. Sanz
J. Sanz

17 December 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
PCPedro Chorão
Pedro Chorão
MVMarta Villalba
Marta Villalba
ABAitana Balaguer-Roselló
Aitana Balaguer-Roselló
JMJuan Montoro
Juan Montoro
PGPablo Granados
Pablo Granados
JSJaime Sanz
Jaime Sanz
BK hemorrhagic cystitis (BK-HC) is a common complication following hematopoietic stem cell transplantation (HSCT), particularly when posttransplant cyclophosphamide (PTCy) is used as graft-versus-host disease (GVHD) prophylaxis. However, comparative studies of BK-HC incidence in matched sibling donors (MSD) and unrelated donors (MUD) often include small haploidentical (HAPLO) donor cohorts and usually lack detailed information on disease evolution, coinfections, management and impact on outcomes. This study aimed to evaluate the incidence, risk factors, and outcomes in patients with hematologic malignancies undergoing HSCT from MSD, MUD, HAPLO donors using PTCy as GVHD prophylaxis. Furthermore, we analyze risk factors for BK-HC and its impact on renal function and transplant outcomes. Retrospective analysis of BK-HC episodes in patients undergoing HSCT from 167 MSD, 129 MUD and 103 HAPLO from a single institution. Uniform GVHD prophylaxis with PTCy, sirolimus and mycophenolate mofetil was given, irrespective of donor type or conditioning intensity, and mesna was used prophylactically with PTCy. The incidence of grade 2-4 BK-HC was 23%, with a higher prevalence of grades 3-4 in HAPLO (19%), compared to MSD (11%) and MUD (8%) recipients (p=0.02). BK-HC was diagnosed at a median of 29 days after HSCT and symptoms persisted for a median of 27 days, with longer duration in grade 3-4 cases (p=0.02). Additionally, higher grades were associated with a greater transfusion burden (p<0.001). JC virus coinfection was detected in 24%, and cytomegalovirus viruria in 17%, which was not treated. BK antiviral treatment beyond supportive care was used in only two patients, while antibacterial treatments were prescribed in 28% for urinary symptoms and in 57% for concomitant infections in other sites. Younger age and HAPLO donors were significant risk factors for developing higher-grade BK-HC. No interaction was seen between age and conditioning intensity. Importantly, BK-HC did not significantly impact overall survival or graft-versus-host disease-free relapse-free survival as a time-dependent variable, as well as non-relapse mortality. Furthermore, BK-HC patients maintained stable creatinine renal clearance at 1 year post-transplant. BK-HC is a relatively early frequent complication in allogeneic HSCT with PTCy, especially in HAPLO recipients, with symptoms typically lasting a median of three weeks. Supportive care remains the mainstay of treatment, while specific antiviral treatments are rarely needed. The role of cidofovir and concomitant CMV viruria treatment are yet to be established. Our findings suggest that BK-HC does not significantly impact transplant outcomes and renal function.

25 June 2024 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
Miguel SanzMiguel Sanz
Miguel Sanz
JMJuan Montoro
Juan Montoro
ABAitana Balaguer-Roselló
Aitana Balaguer-Roselló
PCPedro Chorão
Pedro Chorão
MVMarta Villalba
Marta Villalba
JSJaime Sanz
Jaime Sanz

23 April 2025 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
RBRafael Benavente
Rafael Benavente
JMJuan Montoro
Juan Montoro
ABAitana Balaguer-Roselló
Aitana Balaguer-Roselló
MVMarta Villalba
Marta Villalba
PCPedro Chorão
Pedro Chorão
JSJaime Sanz
Jaime Sanz

12 May 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
PCPedro Asensi Cantó
Pedro Asensi Cantó
MMMiguel Mansilla-Polo
Miguel Mansilla-Polo
JMJuan Montoro
Juan Montoro
ABAitana Balaguer-Roselló
Aitana Balaguer-Roselló
MVMarta Villalba
Marta Villalba
JSJaime Sanz
Jaime Sanz